A review of the latest clinical trials on the use of cannabinoids in the treatment of multiple sclerosis
MS Report · 30.09.2025 · 14 (2(51)) · 20-28
DOI: 10.24292/01.ms.142300625 ↗Kurz gefasst
Fachartikel in der Zeitschrift MS Report, online erschienen am 30.09.2025. Verfasst von Katarzyna Ziętal.
Abstract (Originalsprache)
Cannabinoids represent one therapeutic option for the symptomatic treatment of multiple sclerosis. Clinical trial results indicate that the use of a preparation containing a mixture of tetrahydrocannabinol and cannabidiol may provide a moderate yet clinically significant improvement in spasticity in patients for whom standard treatment is ineffective, which led to the approval of this preparation. According to patients, it provides subjectively perceived benefits, although many objective analyses do not show a statistically significant improvement between the group receiving the cannabis-based preparation and the control group receiving a placebo. Data on its effects on other symptoms, such as sleep disturbances, bladder function, or quality of life, remain inconclusive and require further research. The safety profile of approved cannabinoid preparations is considered acceptable; however, adverse effects such as drowsiness, dizziness, or mood swings may limit tolerability in some patients. Current evidence supports the use of cannabinoids as an alternative therapy, particularly for treatment-resistant spasticity, while emphasizing the need for further, more advanced studies to definitively confirm their efficacy.
Zitieren
APA
Ziętal, K. (2025). A review of the latest clinical trials on the use of cannabinoids in the treatment of multiple sclerosis. MS Report, 14(2(51)), 20-28. https://doi.org/10.24292/01.ms.142300625
Vancouver
Ziętal K. A review of the latest clinical trials on the use of cannabinoids in the treatment of multiple sclerosis. MS Report. 2025;14(2(51)):20-28. doi:10.24292/01.ms.142300625
BibTeX
@article{Zital2025,
author = {Ziętal, Katarzyna},
title = {A review of the latest clinical trials on the use of cannabinoids in the treatment of multiple sclerosis},
journal = {MS Report},
year = {2025},
volume = {14},
number = {2(51)},
pages = {20--28},
doi = {10.24292/01.ms.142300625}
}
EUVIMED